Founded
2016
CEO
Ros Deegan
Founder
Professor Dame Carol Robinson
% Shareholding
49%
Stage
Pre-clinical
Number of employees
30+
Raised in an expanded Series A financing in February 2020
£27.5m

Unless stated all figures at 31 March 2021

Omass website

OMass Therapeutics is an Oxford University spin-out backed by Syncona and Oxford Sciences Innovation that is harnessing high-resolution native mass spectrometry and other biophysical technologies to drive drug discovery in high definition for immunology and genetic disease.

OMass uses its suite of proprietary technologies based on high-resolution mass spectrometry to study intact protein assemblies. The technology enables detection of drug leads that not only bind to the target complex, but also exert a functional effect through modulation of complex formation, with both effects, binding and function, being measured by a change in mass. These methods are being applied to drug discovery for a variety of complex targets, focusing on membrane receptors.

The platform is based on work initiated by its scientific founders in the laboratory of Professor Carol Robinson at Oxford University and is currently being applied to G-protein coupled receptors and other membrane proteins where they have developed a portfolio of intellectual property protection. Omass are optimising and automating their approach and this is part-funded by an Innovate Grant, awarded in March 2018.

OMass have initiated programs against three high impact G-protein coupled receptor targets (GPCRs) with a focus on genetically defined patient populations and/or immunological dysfunction. Currently actively evaluating additional GPCRs and solute carriers aligned with their focus on immunology and genetic disease.

OMass’ strategy is to discover, develop and ultimately commercialise a pipeline of small molecule therapeutics that bring life-changing benefits to patients suffering from immunology and genetic disorders. They are open to strategic collaborations in high value areas where they can combine their proprietary technology with a partner’s biology expertise.

Investment opportunity

  • Opportunity to develop differentiated small molecule drugs leveraging a world-leading Native Mass Spectrometry platform which enables unique insights into membrane proteins and protein complexes such as GPCRs and Solute Carriers – classes of targets that have been historically difficult to drug in spite of high clinical relevance and unmet need.

Unmet medical need

  • Undisclosed programmes are all in indications with significant unmet medical need

Key risks

  • Attrition of potential drugs

The Omass Therapeutics pipeline

Research Pre-clinical Clinical
  • Undisclosed programmes

Syncona team

Martin Murphy

Martin Murphy

Martin is Chief Executive Officer of Syncona Investment Management Ltd. He co-founded Syncona in 2012 alongside The Wellcome Trust. Since then, Martin has been closely involved in the foundation and development of seven Syncona companies, including: Achilles Therapeutics, Autolus, OMass Therapeutics, Quell Therapeutics, Anaveon and Resolution Therapeutics. He is Chairman of Autolus, Quell and Anav…
View Martin's biography
Position
Board observer
Qualification
PhD
Magdalena Jonikas

Magdalena Jonikas

Magdalena is a Partner of Syncona Investment Management Ltd. She is a Director on the Board of OMass Therapeutics. Previously, she was an Associate Partner at McKinsey & Company where she specialised in pharmaceuticals Research & Development, portfolio management and Business Development and Licensing. Magdalena holds a PhD in Bioengineering from Stanford University and was a postdoctoral…
View Magdalena's biography
Position
Board member
Qualification
PhD
Edward Hodgkin

Edward Hodgkin

Edward Hodgkin is a Partner of Syncona Investment Management Ltd. He is currently Chairman & CEO of Resolution Therapeutics and Chairman of OMass Therapeutics, and was previously the first CEO and a board member of Autolus Therapeutics (NASDAQ:AUTL). Within the Syncona life science team, he is involved in creation of new businesses and then fills executive roles within those companies to make…
View Edward's biography
Position
Chair
Qualification
PhD

OMass Therapeutics leaders and founders

Professor Dame Carol Robinson

Professor Dame Carol Robinson

Founder and Scientific Advisor
Dr Jonathan Hopper

Dr Jonathan Hopper

Founder and Vice President, Platforms
Dr Idlir Liko

Dr Idlir Liko

Founder and Director of Technology